Organization
University of California at San Diego
3 abstracts
Abstract
Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data.Org: University of California, San Francisco Medical Center, University of North Carolina, Lineberger Comprehensive Cancer Center, University of Chicago, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Duke Cancer Institute,
Abstract
Impact of COVID-19 pandemic on the treatment of prostate cancer in the Brazilian Public Health System.Org: LACOG - Latin American Cooperative Oncology Group, University of California, San Diego (UCSD), University of California at San Diego, Univeristy of California San Diego, Hospital Beneficência Portuguesa de São Paulo, São Paulo, Brazil,
Abstract
ACHIEVING COMPREHENSIVE DISEASE CONTROL IN LONG-STANDING OR EARLY RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ADALIMUMAB PLUS METHOTREXATE VERSUS METHOTREXATE ALONE Org: AbbVie, Leiden University Medical Center, The Karolinska Institute, Stockholm, Sweden, AbbVie Inc., North Chicago, IL, AbbVie Deutschland GmbH & Co KG,